A comparative analysis of liver tissue and novel primary organoid cultures from ruminants reveals species-specific immune architecture and metabolic specialization

This study establishes the first bovine and ovine liver organoid models derived from primary tissue, revealing species-specific differences in immune and metabolic gene expression while validating their utility for studying liver function, drug metabolism, and toxicity in ruminants.

The Gist

Imagine the liver as the body's super-efficient chemical processing plant. It filters toxins, manages energy, and produces bile to help digest food. For a long time, scientists have been able to build tiny, 3D "mini-livers" (called organoids) from human, mouse, and pig cells to study diseases and test drugs without hurting animals. But there was a missing piece: no one knew how to build these mini-livers for cows and sheep.

This paper is the story of how scientists finally cracked the code to grow liver organoids from cattle and sheep, and what they discovered about the surprising differences between these two animals that we usually think of as very similar.

Here is the breakdown of their journey:

1. The Construction Project: Building the Mini-Livers

Think of the liver as a city. It has two main types of workers:

• Hepatocytes: The heavy-duty factory workers who do the actual chemical processing (detox, energy).
• Cholangiocytes: The plumbing crew who manage the pipes (bile ducts).

The scientists took tiny pieces of the "plumbing" (ducts) from real cow and sheep livers and put them in a special nutrient gel (like a high-tech soil).

• The Result: Just like seeds sprouting, these pieces grew into tiny, hollow, 3D spheres. These were the organoids.
• The Catch: The sheep organoids were like tough, resilient weeds; they grew happily for months and could be split and replanted over and over again. The cow organoids, however, were like delicate flowers; they grew well at first but started to wilt and die after about four or five "generations" (passages).

2. The Detective Work: Why are they different?

Since the cow and sheep organoids behaved so differently, the scientists put on their detective hats and looked at the genetic blueprints (RNA) of both. They found some fascinating secrets:

• The Cow's "Stress Mode": The cow organoids were constantly buzzing with inflammatory signals (like a fire alarm that won't stop ringing). Specifically, they had high levels of a protein called TNF. This constant "stress" might be why the cow organoids eventually crashed and died. It's like trying to run a marathon while your body is screaming "STOP!"
• The Sheep's "Protective Shield": The sheep organoids had a different genetic profile focused on protection and repair. They were better at handling stress without shutting down, which is why they could be grown for so long.
• The Fat Factory vs. The Fat Burner:
  • Cows are genetically wired to be fat storage units. Their livers are great at grabbing fat and storing it. This explains why cows are prone to "fatty liver disease" (hepatic lipidosis) when they get stressed or stop eating.
  • Sheep are wired to be fat burners. Their livers are better at taking that fat and converting it into energy. They are less likely to get fatty liver disease.

3. The Drug Test: Can they work?

The ultimate test for a mini-liver is: Can it actually do the job of a real liver?
The scientists gave the organoids a common livestock medicine called Triclabendazole (used to treat liver flukes in sheep and cattle).

• The Result: Both the cow and sheep organoids successfully took the drug, processed it, and turned it into its active form (a chemical change called "sulfoxidation").
• The Takeaway: These tiny spheres aren't just pretty balls of cells; they are functional factories that can metabolize drugs just like a real liver. This means scientists can now test new medicines on these mini-livers in a dish, potentially saving real animals from unnecessary testing.

4. Why This Matters

Before this study, if a scientist wanted to study liver disease in a cow, they had to use a real cow (expensive, hard to control, and raises ethical concerns) or use a human cell line (which doesn't work exactly like a cow).

Now, they have a new tool:

1. For Sheep: A robust, long-lasting model to study liver health and drug safety.
2. For Cows: A model that, while harder to keep alive long-term, reveals why cows are so susceptible to fatty liver disease and inflammation.

The Big Picture Analogy

Think of the liver as a car engine.

• For years, we could only build miniature engines for human cars and race cars (mice/pigs).
• This paper is the first time we successfully built a miniature engine for a tractor (cow) and a sheepdog (sheep).
• We discovered that the tractor engine is built to haul heavy loads (store fat) but overheats easily (inflammation), while the sheepdog engine is built for agility and burning fuel efficiently.
• Now, instead of taking apart a real tractor to see how it works, we can run tests on these tiny, safe, miniature versions in the lab.

This study doesn't just give us new lab tools; it gives us a deeper understanding of why cows and sheep, despite looking similar, have very different internal "operating systems" when it comes to their health.

Technical Summary

1. Problem Statement

The liver is a highly conserved organ across vertebrates, yet there is a critical lack of physiologically relevant in vitro models for ruminants (specifically cattle and sheep).

• Current Limitations: Existing models rely on immortalized cell lines (e.g., BFH12) which often fail to recapitulate the complex microenvironment, metabolic functions, and regenerative capabilities of native tissue.
• Industry Impact: Ruminants suffer from significant metabolic liver diseases (e.g., hepatic lipidosis/fatty liver, ketosis) and infectious diseases (viral, bacterial, parasitic), causing billions in economic losses and welfare issues.
• Knowledge Gap: There is insufficient fundamental understanding of ruminant hepatic repair mechanisms, host-pathogen interactions, and species-specific metabolic pathways due to the absence of robust culture systems.

2. Methodology

The study established and characterized primary liver organoids derived from bovine and ovine hepatic ductal fragments.

• Source Material: Liver tissue was obtained post-mortem from Holstein-Friesian calves (two cohorts: 8-day and 9-month-old) and Texel cross sheep (9-month-old).
• Organoid Establishment:
  • Hepatic ductal fragments were isolated via enzymatic digestion (Type I collagenase).
  • Fragments were embedded in Matrigel™ and cultured in Hepaticult Organoid Growth Media (OGM) containing WNT3A, FGF10, HGF, Forskolin, and TGF-β inhibitor (A83.01).
  • Cultures were passaged mechanically and maintained for up to 20 passages (ovine) or ~4 passages (bovine).
• Differentiation Protocol: Organoids were switched to Hepaticult Organoid Differentiation Media (ODM) containing Dexamethasone and TNF-α to induce hepatocyte-like differentiation.
• Characterization Techniques:
  • Transcriptomics: RNA sequencing (RNA-seq) was performed on tissue, OGM-cultured organoids, and ODM-differentiated organoids. Analysis included Principal Component Analysis (PCA), Differential Gene Expression (DEG), and Gene Set Enrichment Analysis (GSEA) using a human liver single-cell atlas as a reference.
  • Protein Analysis: Immunohistochemistry (IHC) and Western blotting were used to validate markers (KRT19, KRT18, Albumin/ALB, Ki67).
  • Functional Assay: Organoids were treated with Triclabendazole (TCBZ) (20 µM) for 24 hours. Metabolism was assessed via Liquid Chromatography-Mass Spectrometry (LC-MS/MS) to detect the conversion of TCBZ to its primary metabolite, TCBZ-sulfoxide (TCBZ-SO).

3. Key Contributions

• First Ruminant Organoids: This study reports the first successful derivation and comprehensive characterization of primary liver organoids from both cattle and sheep.
• Species-Specific Biology: It reveals that despite the liver being considered a conserved organ, cattle and sheep possess fundamental, conserved differences in immune architecture and metabolic specialization that are retained in organoid cultures.
• Functional Validation: The study validates these organoids as functional models for drug metabolism, specifically demonstrating the biotransformation of a veterinary drug (TCBZ).

4. Key Results

A. Organoid Establishment and Stability

• Morphology: Both species formed spherical, hollow-lumen structures within 24–48 hours.
• Passaging:
  • Ovine: Highly stable; maintained for >20 passages with consistent phenotype.
  • Bovine: Limited stability; cultures typically "crashed" (failed to reform after passaging) by passage 3 or 4, characterized by darkening and loss of lumen.
• Cell Identity: In OGM, organoids from both species were enriched for cholangiocyte markers (KRT19+, KRT18+, EPCAM+), confirming their origin from ductal progenitor cells.

B. Differentiation Potential

• Bovine: Switching to ODM induced a clear shift toward hepatocyte-like cells.
  • Morphology: Cells became darker and denser.
  • Markers: Significant upregulation of ALB (Albumin) and urea cycle genes; downregulation of proliferation marker MKI67 and cholangiocyte marker KRT19.
  • Limitation: Bovine organoids could not be cultured long-term in OGM, and adding TNF-α (often used to drive differentiation) caused rapid cell death, suggesting endogenous TNF-α levels were already elevated.
• Ovine: Differentiation was less complete.
  • Markers: ALB expression remained high in OGM and did not significantly increase in ODM. Urea cycle gene upregulation was minimal (only BHMT increased).
  • Conclusion: Ovine organoids retain a mixed cholangiocyte/hepatocyte phenotype even in differentiation media, unlike the more distinct switch seen in bovine cultures.

C. Species-Specific Transcriptomic Signatures

Comparative analysis revealed ~5,000 differentially expressed genes (DEGs) between species, with ~850–900 DEGs conserved across tissue and organoid conditions.

• Immune Landscape:
  • Bovine: Enriched in inflammatory and cytotoxic markers (e.g., TNF, IL-1β, VSIG4). High endogenous TNF-α likely contributes to the culture instability ("crashing").
  • Ovine: Enriched in protective and anti-apoptotic markers (e.g., ICOS, IFI6, EOLA1), correlating with higher culture stability.
• Metabolic Specialization:
  • Bovine: Enriched in genes for fatty acid uptake and storage (e.g., LPL, LIPC, DGAT2L6). This aligns with the known susceptibility of cattle to hepatic lipidosis.
  • Ovine: Enriched in genes for fatty acid β-oxidation and conversion (e.g., ACADL, ACAD9, ACAD11), suggesting a metabolic bias toward processing rather than storing lipids.
• Xenobiotic Metabolism:
  • Receptors: Ovine samples enriched for PXR (NR1I2); Bovine samples enriched for CAR (NR1I3).
  • Cytochrome P450 (CYP): Significant species-specific differences in CYP expression profiles, including unique genes annotated only in the bovine or ovine genomes.

D. Functional Drug Metabolism

• Both bovine and ovine organoids successfully metabolized Triclabendazole (TCBZ) into TCBZ-sulfoxide (TCBZ-SO).
• Metabolites were detected in both the cellular fraction and the culture supernatant, confirming active uptake, intracellular biotransformation, and secretion.
• Expression of Flavin-containing Monooxygenase (FMO) genes, crucial for this pathway, was confirmed in both species.

5. Significance

• Novel Research Tool: Provides the first robust in vitro platform for studying ruminant liver biology, reducing reliance on live animal trials (adhering to 3Rs principles).
• Disease Modeling: The species-specific metabolic differences (lipid storage vs. oxidation) offer a mechanistic explanation for the differential susceptibility of cattle and sheep to fatty liver disease, allowing for targeted therapeutic research.
• Drug Development: Validates the utility of these organoids for pre-clinical screening of veterinary drugs and toxins, particularly for compounds metabolized by CYP and FMO enzymes.
• Biological Insight: Challenges the assumption of liver homogeneity across ruminants, highlighting that even closely related species have distinct immune and metabolic architectures that must be accounted for in translational research.